進行性核上性麻痺:治療薬開発パイプライン分析

Global Markets Directが発行した調査報告書(GMDHC9963IDB)
◆英語タイトル:Progressive Supranuclear Palsy - Pipeline Review, H2 2017
◆商品コード:GMDHC9963IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2017年12月29日
◆ページ数:80
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥224,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥448,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥672,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

当調査レポートでは、世界における進行性核上性麻痺の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。
・イントロダクション
・進行性核上性麻痺の概要
・進行性核上性麻痺治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・進行性核上性麻痺パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・企業別、開発中の製品
・大学/研究機関別、研究中の製品
・進行性核上性麻痺治療薬開発に取り組んでいる企業:企業別製品パイプライン
・進行性核上性麻痺治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Progressive Supranuclear Palsy – Pipeline Review, H2 2017

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Progressive Supranuclear Palsy – Pipeline Review, H2 2017, provides an overview of the Progressive Supranuclear Palsy (Central Nervous System) pipeline landscape.

Progressive supranuclear palsy, also called Steele-Richardson-Olszewski syndrome is a rare neurodegenerative disease that leads to difficulty with balance, movement, vision, speech and swallowing. Symptoms include fatigue, headaches, dizziness, depression, Parkinsonism, behavioral, cognitive, and gait disturbances that cause imbalance and arthralgias. The only proven risk factor for progressive supranuclear palsy is age. Treatment includes anticholinergic medications.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Progressive Supranuclear Palsy – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Progressive Supranuclear Palsy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Progressive Supranuclear Palsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Progressive Supranuclear Palsy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Unknown stages are 1, 3, 5, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Progressive Supranuclear Palsy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Progressive Supranuclear Palsy (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Progressive Supranuclear Palsy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Progressive Supranuclear Palsy (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Progressive Supranuclear Palsy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Progressive Supranuclear Palsy (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Progressive Supranuclear Palsy (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Progressive Supranuclear Palsy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Progressive Supranuclear Palsy – Overview
Progressive Supranuclear Palsy – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Progressive Supranuclear Palsy – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Progressive Supranuclear Palsy – Companies Involved in Therapeutics Development
AB Science SA
AbbVie Inc
AlzProtect SAS
Asceneuron SA
Biogen Inc
Cortice Biosciences Inc
Intellect Neurosciences Inc
K-Stemcell Co Ltd
Merck & Co Inc
Prana Biotechnology Ltd
TauRx Therapeutics Ltd
UCB SA
Progressive Supranuclear Palsy – Drug Profiles
ABBV-8E12 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASN-120290 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZP-2006 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DC-TAB – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DPC-016 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gosuranemab – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
masitinib – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-8719 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit Tau for Progressive Supranuclear Palsy – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PBT-434 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Spinal Cord Injury, Alzheimer’s Disease, Progressive Supranuclear Palsy and Cerebral Palsy – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TauC-3 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tolfenamic acid – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TPI-287 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TRx-0237 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Progressive Supranuclear Palsy – Dormant Projects
Progressive Supranuclear Palsy – Product Development Milestones
Featured News & Press Releases
Nov 03, 2017: Cortice Biosciences Announces Presentation of Results from Placebo-Controlled Phase 1 Clinical Trials Evaluating TPI 287 for Treatment of Alzheimer’s Disease and Related Tauopathies
May 04, 2017: AlzProtect : The American Food and Drug Administration (FDA) Has Granted AZP2006 the Orphan Drug Designation for the Treatment of Progressive Supranuclear Palsy (PSP)
Apr 04, 2017: Asceneuron Receives Approval for Phase I Study of Oral Tau Inhibitor
Jan 25, 2017: AbbVie Initiates Phase 2 Clinical Trial Programs for ABBV-8E12, an Investigational Anti-Tau Antibody, in Early Alzheimer’s Disease and Progressive Supranuclear Palsy
Oct 13, 2016: C2N Diagnostics Completes Phase 1 Clinical Study of C2N-8E12 (ABBV-8E12) Among Individuals with Progressive Supranuclear Palsy
Jul 17, 2015: C2N And Abbvie Announce FDA Orphan Drug Designation Of C2N-8E12 (ABBV-8E12) For The Treatment Of Progressive Supranuclear Palsy
Jul 07, 2014: Cortice Announces Enrollment of a Phase 1 Clinical Trial Evaluating TPI 287 in Rare Tauopathy Diseases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Progressive Supranuclear Palsy, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Progressive Supranuclear Palsy - Pipeline by AB Science SA, H2 2017
Progressive Supranuclear Palsy - Pipeline by AbbVie Inc, H2 2017
Progressive Supranuclear Palsy - Pipeline by AlzProtect SAS, H2 2017
Progressive Supranuclear Palsy - Pipeline by Asceneuron SA, H2 2017
Progressive Supranuclear Palsy - Pipeline by Biogen Inc, H2 2017
Progressive Supranuclear Palsy - Pipeline by Cortice Biosciences Inc, H2 2017
Progressive Supranuclear Palsy - Pipeline by Intellect Neurosciences Inc, H2 2017
Progressive Supranuclear Palsy - Pipeline by K-Stemcell Co Ltd, H2 2017
Progressive Supranuclear Palsy - Pipeline by Merck & Co Inc, H2 2017
Progressive Supranuclear Palsy - Pipeline by Prana Biotechnology Ltd, H2 2017
Progressive Supranuclear Palsy - Pipeline by TauRx Therapeutics Ltd, H2 2017
Progressive Supranuclear Palsy - Pipeline by UCB SA, H2 2017
Progressive Supranuclear Palsy - Dormant Projects, H2 2017

List of Figures
Number of Products under Development for Progressive Supranuclear Palsy, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

【レポートのキーワード】

進行性核上性麻痺

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 進行性核上性麻痺:治療薬開発パイプライン分析(Progressive Supranuclear Palsy - Pipeline Review, H2 2017)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆